Last €1.76 EUR
Change Today +0.005 / 0.29%
Volume 7.9K
NAT On Other Exchanges
Symbol
Exchange
Berlin
Continuous
As of 10:54 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

natra sa (NAT) Snapshot

Open
€1.75
Previous Close
€1.75
Day High
€1.78
Day Low
€1.75
52 Week High
10/23/13 - €2.68
52 Week Low
07/24/13 - €1.53
Market Cap
83.3M
Average Volume 10 Days
32.5K
EPS TTM
€-0.02
Shares Outstanding
47.5M
EX-Date
07/29/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NATRA SA (NAT)

Related News

No related news articles were found.

natra sa (NAT) Related Businessweek News

No Related Businessweek News Found

natra sa (NAT) Details

Natra, S.A., through its subsidiaries, produces, prepares, and markets cocoa derivatives and chocolate products for the private label brand and other food companies. Its products include cocoa mass, cocoa butter, cocoa powder, bulk chocolate, chocolate powder, chocolate bars, tablets, and Belgian chocolates, as well as chocolate coating, specialties and seasonal products, organic products, fair trade, UTZ, and spreads and fillings. The company also offers nutritional supplements. It has operations in 75 countries worldwide. The company was founded in 1950 and is headquartered in Madrid, Spain.

Founded in 1950

natra sa (NAT) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: €187.8K
Compensation as of Fiscal Year 2012.

natra sa (NAT) Key Developments

Natra, S.A., Annual General Meeting, Jun 27, 2014

Natra, S.A., Annual General Meeting, Jun 27, 2014., at 16:00 Central European Standard Time. Location: Paseo Alameda, 32, SH Valencia Palace Hotel. Agenda: To consider the approval of Natra S.A.'s individual and consolidated financial statements for the year ended on December 31, 2013; to consider fixation of the number of board directors within the minimum and maximum limits provided by the bylaws; to consider authorization to the board of directors for the derivative acquisition of treasury stock, either directly or through subsidiaries; to consider authorization and delegation to the board of directors to issue debentures, bonds, redeemable shares, warrants and/or other similar securities, bonds and/or convertible and/or exchangeable bonds into shares of the company and, if required, the power to exclude the preferential subscription rights in accordance with Article 506 of the corporations Act; and to consider other things.

Natra, S.A. Presents at 10th Foro MedCap, May-27-2014

Natra, S.A. Presents at 10th Foro MedCap, May-27-2014 . Venue: Palacio de la Bolsa, Plaza de la Lealtad, 1, 28014 Madrid, Spain.

Natra, S.A. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Natra, S.A. announced consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, net business turnover was EUR 85,805,000, profit from operations was EUR 2,489,000, loss before taxes was EUR 926,000, loss from continued operations was EUR 1,100,000, net loss was EUR 1,100,000 and loss attributable to shareholders of the main company was EUR 2,344,000 against net business turnover of EUR 88,109,000, profit from operations of EUR 5,035,000, profit before taxes of EUR 2,208,000, results from continued operations of EUR 1,616,000, net result of EUR 1,601,000 and loss attributable to shareholders of the main company of EUR 245,000 a year ago. At March 31, 2014, Natra's net financial debt stood at EUR 153.19 million, 1.3 less than at year-end 2013. The difference in net profit is mainly due to the above-mentioned reasons relative to the deterioration of the business' operational profitability due to the impact of increased cocoa prices during the cocoa and chocolate business' off-season, coupled with the change in the pharmaceutical channel's procurement model in the case of Natraceutical. As a direct result of this fact, and despite a reduction in operating costs, the EBITDA for the first quarter was adjusted to EUR 2.61 million, compared to EUR 2.94 million in the same period during the previous year. Meanwhile, net income stood at EUR 2.52 million, compared to EUR 2.88 million in the first quarter of 2013. The EBITDA of the cocoa and chocolate business in the first quarter of the year was EUR 2.73 million, compared to EUR 4.90 million in the first quarter of 2013, in accordance with the company's expectations. This evolution of the turnover was mainly due to the weak consumption in Europe, responsible for 90.6% of the business' total sales, and which registered a drop in sales of 2.2% for Natra's overall cocoa and chocolate activity. The company reported EBITDA of EUR 5.34 million, decreased 46.6%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAT:SM €1.76 EUR +0.005

NAT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natraceutical SA €0.24 EUR -0.003
View Industry Companies
 

Industry Analysis

NAT

Industry Average

Valuation NAT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 1.0x
Price/Cash Flow 9.9x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATRA SA, please visit www.natra.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.